A multi-institutional team developed a chimeric antigen receptor (CAR) T cell-based strategy for specifically targeting AML cells in patients who relapsed following other treatments. The team ...
Relapsed acute myeloid leukemia (AML) is when cancer returns after a period of remission. Refractory AML means cancer has not responded to multiple rounds of treatment. Both can affect your treatment ...
NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of ...
This session from Compliance Week’s 2022 virtual Third-Party Risk Management & Oversight Summit features Phil Palmer, ethics and compliance program manager at Shell UK, moderating a discussion with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback